<DOC>
	<DOCNO>NCT02739009</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose-escalation , phase I study assessment safety , tolerability pharmacokinetics single ascend dos MOR106 healthy male subject multiple ascend dos subject moderate severe atopic dermatitis .</brief_summary>
	<brief_title>First Human Single Multiple Doses MOR106</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Able willing give voluntary write informed consent Single ascend dose ( SAD ) Negative urine drug screen Male 1850 year age A body mass index ( BMI ) 1830 kg/m² , inclusive . Judged good health Multiple ascend dose ( MAD ) Male female 1865 year age A BMI 1830 kg/m² Diagnosis Atopic Dermatitis ( AD ) least 6 month per Hanifin Rajka Criteria EASI ≥ 16 screen baseline visit IGA score ≥3 ( 0 4 IGA scale , 3 moderate 4 severe ) screen baseline visit Greater equal 10 % body surface area ( BSA ) AD involvement screen Willingness continue stable use additive free , basic , bland emollient twice daily least 7 day baseline visit Subject candidate systemic therapy respond adequately contraindication topical corticosteroid and/or topical calcineurin inhibitor ( per Investigator 's judgement ) Absence current active , latent history tuberculosis ( TB ) infection base medical history determine negative QuantiFERON TB Gold test screen Female subject must negative serum pregnancy test screen negative urine pregnancy test baseline Female subject childbearing potential must use highly effective method contraception 28 day prior first dose study drug , study least 24 week last dose Known hypersensitivity study drug ingredient . History current immunosuppressive condition Symptoms clinically significant illness 3 month initial study drug administration . Any concurrent illness , condition , disability , clinically significant abnormality Treatment drug know welldefined potential toxicity major organ last 3 month precede initial study drug administration . A history significant psychological , neurologic , hepatic , renal , endocrine , cardiovascular , gastrointestinal ( GI ) , pulmonary , metabolic disease . MAD Active ( skin ) infection require systemic antibiotic immunosuppressive/immunomodulating drug phototherapy 4 week prior baseline Treatment topical corticosteroid ( TCS ) topical calcineurin inhibitor ( TCI ) within 2 week baseline Treatment biologics within 5 halflives ( know ) 12 week prior baseline visit history immunosuppression Regular use ( 2 visit per week ) tan booth/ parlor within 4 week screen visit Regular daily use oral nonsteroidal antiinflammatory drug ( NSAIDs ) , except lowdose aspirin ( ≤200 mg/day ) cardioprotection , within 7 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>